ArticleNeurogenetics2016
microRNA profiling: increased expression of miR-147a and miR-518e in progressive supranuclear palsy (PSP).
Article in Neurogenetics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- The Role of MicroRNAs in Progressive Supranuclear Palsy-A Systematic Review.International journal of molecular sciences · 2024Pooled it
- Differentially Expressed miRNAs in Age-Related Neurodegenerative Diseases: A Meta-Analysis.Genes · 2022Pooled it
- MicroRNA as Candidate Biomarkers in Atypical Parkinsonian Syndromes: Systematic Literature Review.Medicina (Kaunas, Lithuania) · 2022Pooled it
- Fluid biomarkers in atypical Parkinsonism: current state and future perspectives.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Progressive Supranuclear Palsy Syndrome: An Overview.IBRO neuroscience reports · 2024Review
- Converging peripheral blood microRNA profiles in Parkinson's disease and progressive supranuclear palsy.Brain communications · 2024Article
- Potential of Non-Coding RNA as Biomarkers for Progressive Supranuclear Palsy.International journal of molecular sciences · 2022Article
- Plasma microRNAs as a Potential Biomarker for Identification of Progressive Supranuclear Palsy.Diagnostics (Basel, Switzerland) · 2022Article
- Genetic and Epigenetic Constructs of Progressive Supranuclear Palsy.Annals of neurosciences · 2022Review
- A cerebrospinal fluid microRNA analysis: Progressive supranuclear palsy.Molecular medicine reports · 2022Article
- Evolving concepts in progressive supranuclear palsy and other 4-repeat tauopathies.Nature reviews. Neurology · 2021Review
- MiR-147: Functions and Implications in Inflammation and Diseases.MicroRNA (Shariqah, United Arab Emirates) · 2021Review
- Review
- Sweet Control: MicroRNA Regulation of the Glycome.Biochemistry · 2020Review
- Epigenome-wide DNA methylation profiling in Progressive Supranuclear Palsy reveals major changes at DLX1.Nature communications · 2018Article
- Profiling of Argonaute-2-loaded microRNAs in a mouse model of frontotemporal dementia with parkinsonism-17.International journal of physiology, pathophysiology and pharmacology · 2018Article
- HOXD-AS1 functions as an oncogenic ceRNA to promote NSCLC cell progression by sequestering miR-147a.OncoTargets and therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Progressive supranuclear palsy is a sporadic neurodegenerative disorder. Genetic, environmental, and possibly epigenetic factors contribute to disease. In order to better understand the potential role of epigenetic changes in progressive supranuclear palsy, we investigated whether some microRNAs and their target genes are dysregulated. We analyzed expression of 372 well-characterized microRNAs in forebrains of a total of 40 patients and of 40 controls using TaqMan arrays and SYBR Green quantitative real-time PCR. The exploratory cohort included forebrains from 20 patients and 20 controls provided by the Erasmus Medical Centre in Rotterdam, Netherlands. Confirmatory samples were from Jacksonville, Florida, and from Melbourne, Australia. Both microRNA profiling and SYBR Green quantitative real-time PCR revealed significant upregulation of miR-147 (miR-147a) and miR-518e in the exploratory cohort. Highly increased expression of these two microRNAs was validated in the confirmatory samples. Target genes of miR-147a (NF1, ACLY, ALG12) and of miR-518e (CPEB1, JAZF1, RAP1B) were repressed in patients' forebrains. The results suggest that dysregulation of specific microRNAs contributes to disease by repressing target genes involved in various cellular functions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.